Intranasal Administration of the Combination of Dextro-Ketamine and Dexmedetomidine for Treatment of Diabetic Neuropathic Pain in Rats

Susumu Zapata Sudo,1,* Tadeu Lima Montagnoli,2,* Bruno Eduardo Dematté,3 Aimeé Diogenes Santos,2 Margarete Manhães Trachez,4 Fernanda Gubert,5 Rosalia Mendez-Otero,6 Gisele Zapata-Sudo1– 5 1Programa de Pós-Graduação em Medicina (Cirurgia Geral), Faculdade de Medicina, Universidade Fe...

Full description

Saved in:
Bibliographic Details
Main Authors: Sudo SZ, Montagnoli TL, Dematté BE, Santos AD, Trachez MM, Gubert F, Mendez-Otero R, Zapata-Sudo G
Format: Article
Language:English
Published: Dove Medical Press 2025-01-01
Series:Journal of Pain Research
Subjects:
Online Access:https://www.dovepress.com/intranasal-administration-of-the-combination-of-dextro-ketamine-and-de-peer-reviewed-fulltext-article-JPR
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1841551004505473024
author Sudo SZ
Montagnoli TL
Dematté BE
Santos AD
Trachez MM
Gubert F
Mendez-Otero R
Zapata-Sudo G
author_facet Sudo SZ
Montagnoli TL
Dematté BE
Santos AD
Trachez MM
Gubert F
Mendez-Otero R
Zapata-Sudo G
author_sort Sudo SZ
collection DOAJ
description Susumu Zapata Sudo,1,* Tadeu Lima Montagnoli,2,* Bruno Eduardo Dematté,3 Aimeé Diogenes Santos,2 Margarete Manhães Trachez,4 Fernanda Gubert,5 Rosalia Mendez-Otero,6 Gisele Zapata-Sudo1– 5 1Programa de Pós-Graduação em Medicina (Cirurgia Geral), Faculdade de Medicina, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil; 2Programa de Pós-Graduação em Farmacologia e Química Medicinal, Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil; 3Programa de Pós-Graduação em Medicina (Cardiologia), Instituto do Coração Edson Saad, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil; 4Instituto do Coração Edson Saad, Faculdade de Medicina, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil; 5Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil; 6Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil*These authors contributed equally to this workCorrespondence: Gisele Zapata-Sudo, Instituto do Coração Edson Saad, Faculdade de Medicina, Universidade Federal do Rio de Janeiro, Rio de Janeiro, 21941-902, Brazil, Email gsudo@icb.ufrj.br; gzsudo@gmail.comIntroduction: Diabetes mellitus (DM) has become a public health problem, which is associated with high morbidity and mortality, due to the chronic complications, such as diabetic neuropathy. Current recommendations for the treatment of neuropathic pain achieve a reduction of 30% in only 30% of cases. Therefore, it is necessary to identify new therapeutic approaches to improve the quality of life of diabetic patients.Methods: This work evaluated the antinociceptive effect of intranasal administration of the combination of dextro-ketamine (keta), a non-competitive glutamatergic receptor antagonist, and dexmedetomidine (DEX), a selective alpha2-adrenergic agonist, in rats with neuropathic pain induced by streptozotocin-DM.Results: The thermal hyperalgesia and mechanical allodynia observed in DM model are reduced with the intranasal administration of the combination of keta and DEX (200 + 0.10 μg/kg) after 3 days of treatment. The antinociceptive action could be due to reduction of Ca2+ influx with lower glutamate release and reduced excitability through the activation of alpha2-adrenergic receptors by DEX and reduction of NMDA receptor activation by glutamate with lower excitability due to the antagonism produced by keta. DM induced increased expression of glial fibrillary acid protein (GFAP) and tumor necrosis factor-alpha (TNF-alpha) detected by immunohistochemistry, indicating greater astrocyte activity and intense inflammatory response. Intranasal administration for 10 days of the combination of low doses of keta and DEX promoted an intense decrease in the expression of both GFAP and TNF-alpha, indicating lower activation of astrocytes in the spinal cord and reduced production and release of TNF-alpha, favoring the reduction of inflammation.Conclusion: Intranasal administration of low doses of keta with DEX could be a new therapeutic approach to reduce neuropathic pain and consequently improve the quality of life of diabetic patients.Keywords: diabetes, neuropathic pain, dextro-ketamine, dexmedetomidine
format Article
id doaj-art-90e984b1199c45548457cebd4d2f42d1
institution Kabale University
issn 1178-7090
language English
publishDate 2025-01-01
publisher Dove Medical Press
record_format Article
series Journal of Pain Research
spelling doaj-art-90e984b1199c45548457cebd4d2f42d12025-01-09T16:58:35ZengDove Medical PressJournal of Pain Research1178-70902025-01-01Volume 1812713699104Intranasal Administration of the Combination of Dextro-Ketamine and Dexmedetomidine for Treatment of Diabetic Neuropathic Pain in RatsSudo SZMontagnoli TLDematté BESantos ADTrachez MMGubert FMendez-Otero RZapata-Sudo GSusumu Zapata Sudo,1,* Tadeu Lima Montagnoli,2,* Bruno Eduardo Dematté,3 Aimeé Diogenes Santos,2 Margarete Manhães Trachez,4 Fernanda Gubert,5 Rosalia Mendez-Otero,6 Gisele Zapata-Sudo1– 5 1Programa de Pós-Graduação em Medicina (Cirurgia Geral), Faculdade de Medicina, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil; 2Programa de Pós-Graduação em Farmacologia e Química Medicinal, Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil; 3Programa de Pós-Graduação em Medicina (Cardiologia), Instituto do Coração Edson Saad, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil; 4Instituto do Coração Edson Saad, Faculdade de Medicina, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil; 5Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil; 6Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil*These authors contributed equally to this workCorrespondence: Gisele Zapata-Sudo, Instituto do Coração Edson Saad, Faculdade de Medicina, Universidade Federal do Rio de Janeiro, Rio de Janeiro, 21941-902, Brazil, Email gsudo@icb.ufrj.br; gzsudo@gmail.comIntroduction: Diabetes mellitus (DM) has become a public health problem, which is associated with high morbidity and mortality, due to the chronic complications, such as diabetic neuropathy. Current recommendations for the treatment of neuropathic pain achieve a reduction of 30% in only 30% of cases. Therefore, it is necessary to identify new therapeutic approaches to improve the quality of life of diabetic patients.Methods: This work evaluated the antinociceptive effect of intranasal administration of the combination of dextro-ketamine (keta), a non-competitive glutamatergic receptor antagonist, and dexmedetomidine (DEX), a selective alpha2-adrenergic agonist, in rats with neuropathic pain induced by streptozotocin-DM.Results: The thermal hyperalgesia and mechanical allodynia observed in DM model are reduced with the intranasal administration of the combination of keta and DEX (200 + 0.10 μg/kg) after 3 days of treatment. The antinociceptive action could be due to reduction of Ca2+ influx with lower glutamate release and reduced excitability through the activation of alpha2-adrenergic receptors by DEX and reduction of NMDA receptor activation by glutamate with lower excitability due to the antagonism produced by keta. DM induced increased expression of glial fibrillary acid protein (GFAP) and tumor necrosis factor-alpha (TNF-alpha) detected by immunohistochemistry, indicating greater astrocyte activity and intense inflammatory response. Intranasal administration for 10 days of the combination of low doses of keta and DEX promoted an intense decrease in the expression of both GFAP and TNF-alpha, indicating lower activation of astrocytes in the spinal cord and reduced production and release of TNF-alpha, favoring the reduction of inflammation.Conclusion: Intranasal administration of low doses of keta with DEX could be a new therapeutic approach to reduce neuropathic pain and consequently improve the quality of life of diabetic patients.Keywords: diabetes, neuropathic pain, dextro-ketamine, dexmedetomidinehttps://www.dovepress.com/intranasal-administration-of-the-combination-of-dextro-ketamine-and-de-peer-reviewed-fulltext-article-JPRdiabetesneuropathic paindextro-ketaminedexmedetomidine
spellingShingle Sudo SZ
Montagnoli TL
Dematté BE
Santos AD
Trachez MM
Gubert F
Mendez-Otero R
Zapata-Sudo G
Intranasal Administration of the Combination of Dextro-Ketamine and Dexmedetomidine for Treatment of Diabetic Neuropathic Pain in Rats
Journal of Pain Research
diabetes
neuropathic pain
dextro-ketamine
dexmedetomidine
title Intranasal Administration of the Combination of Dextro-Ketamine and Dexmedetomidine for Treatment of Diabetic Neuropathic Pain in Rats
title_full Intranasal Administration of the Combination of Dextro-Ketamine and Dexmedetomidine for Treatment of Diabetic Neuropathic Pain in Rats
title_fullStr Intranasal Administration of the Combination of Dextro-Ketamine and Dexmedetomidine for Treatment of Diabetic Neuropathic Pain in Rats
title_full_unstemmed Intranasal Administration of the Combination of Dextro-Ketamine and Dexmedetomidine for Treatment of Diabetic Neuropathic Pain in Rats
title_short Intranasal Administration of the Combination of Dextro-Ketamine and Dexmedetomidine for Treatment of Diabetic Neuropathic Pain in Rats
title_sort intranasal administration of the combination of dextro ketamine and dexmedetomidine for treatment of diabetic neuropathic pain in rats
topic diabetes
neuropathic pain
dextro-ketamine
dexmedetomidine
url https://www.dovepress.com/intranasal-administration-of-the-combination-of-dextro-ketamine-and-de-peer-reviewed-fulltext-article-JPR
work_keys_str_mv AT sudosz intranasaladministrationofthecombinationofdextroketamineanddexmedetomidinefortreatmentofdiabeticneuropathicpaininrats
AT montagnolitl intranasaladministrationofthecombinationofdextroketamineanddexmedetomidinefortreatmentofdiabeticneuropathicpaininrats
AT demattebe intranasaladministrationofthecombinationofdextroketamineanddexmedetomidinefortreatmentofdiabeticneuropathicpaininrats
AT santosad intranasaladministrationofthecombinationofdextroketamineanddexmedetomidinefortreatmentofdiabeticneuropathicpaininrats
AT trachezmm intranasaladministrationofthecombinationofdextroketamineanddexmedetomidinefortreatmentofdiabeticneuropathicpaininrats
AT gubertf intranasaladministrationofthecombinationofdextroketamineanddexmedetomidinefortreatmentofdiabeticneuropathicpaininrats
AT mendezoteror intranasaladministrationofthecombinationofdextroketamineanddexmedetomidinefortreatmentofdiabeticneuropathicpaininrats
AT zapatasudog intranasaladministrationofthecombinationofdextroketamineanddexmedetomidinefortreatmentofdiabeticneuropathicpaininrats